{"format":1,"id":"118-hr-8333","congress":118,"number":"H.R. 8333","kind":"bill","group":"bills","title":"BIOSECURE Act","title_source":"Short Title(s) as Passed House","official_title":"To prohibit contracting with certain biotechnology providers, and for other purposes.","titles":[{"type":"Official Title as Introduced","title":"To prohibit contracting with certain biotechnology providers, and for other purposes."},{"type":"Short Titles from RFS (Referred to Senate) bill text","title":"BIOSECURE Act"},{"type":"Short Title(s) as Passed House","title":"BIOSECURE Act"},{"type":"Short Title(s) as Introduced","title":"BIOSECURE Act"},{"type":"Display Title","title":"BIOSECURE Act"}],"outcome":"passed_house","law_number":null,"introduced":"2024-05-10","chambers":{"house":{"status":"roll_call","date":"2024-09-09","vote":{"id":"118-2024-h402","question":"On Motion to Suspend the Rules and Pass, as Amended","title":"BIOSECURE Act","result":"Passed","yea":306,"nay":81,"present":0,"not_voting":44,"source":"https://clerk.house.gov/evs/2024/roll402.xml"}},"senate":{"status":"na","date":null,"vote":null}},"president":{"status":"na","date":null},"vice_president_tie_breaker":null,"latest_action":{"text":"Received in the Senate and Read twice and referred to the Committee on Homeland Security and Governmental Affairs.","date":"2024-09-10"},"nominees":null,"amendments":[],"other_votes":[],"crs_summary":{"date":"2024-05-10","stage":"Introduced in House","blocks":[{"k":"h","t":"BIOSECURE Act"},{"k":"p","t":"This bill prohibits entities that receive federal funds from using biotechnology that is from a company associated with a foreign adversary."},{"k":"p","t":"Specifically, federal agencies and recipients of federal funds (e.g., grantees) may not procure or use any biotechnology equipment or service that is from a biotechnology company of concern and may not contract with any entities that do so. A biotechnology company of concern is an entity that is under the control of a foreign adversary and that poses a risk to national security based on its research or multiomic data collection (e.g., collection of genomic information)."},{"k":"p","t":"The Office of Management and Budget (OMB) must, in coordination with the Department of Defense (DOD) and other specified agencies, develop a list of prohibited companies; the list must include five particular companies, as specified in the bill. OMB and DOD may approve waivers of these restrictions on an as-needed basis, which are valid for up to one year and may be extended once for an additional 180 days."},{"k":"p","t":"In addition, the Office of the Director of National Intelligence must report on the national security risks posed by (1) multiomic data collection by foreign adversaries in connection with biotechnology equipment or services, and (2) biotechnology companies that have such data."}],"words":209},"summary":{"main_subject":{"text":"Prohibits executive agencies from procuring biotechnology equipment or services from biotechnology companies of concern, from contracting with entities that use them, and from using loan or grant funds for them.","cites":[{"label":"Sec. 2","href":"https://www.congress.gov/bill/118th-congress/house-bill/8333/text/eh#HFB7578370D68498F99182F950F1097B7"}]},"core_areas":["Federal procurement and contracting prohibitions on biotechnology companies of concern","Restrictions on loan and grant funds","Designation and listing of biotechnology companies of concern","Waivers and exceptions to the prohibitions","National security assessment and intelligence reporting on human multiomic data"],"what_it_does":[{"text":"Prohibits the head of an executive agency from procuring biotechnology equipment or services from a biotechnology company of concern, and from entering into, extending or renewing a contract with certain entities that use such equipment or services.","cite":{"label":"Sec. 2","href":"https://www.congress.gov/bill/118th-congress/house-bill/8333/text/eh#HFB7578370D68498F99182F950F1097B7"}},{"text":"Prohibits executive agencies from obligating or spending loan or grant funds, and loan or grant recipients from using those funds, to procure or use such equipment or services or to contract with those entities.","cite":{"label":"Sec. 2","href":"https://www.congress.gov/bill/118th-congress/house-bill/8333/text/eh#HFB7578370D68498F99182F950F1097B7"}},{"text":"Names BGI, MGI, Complete Genomics, WuXi AppTec, and WuXi Biologics as biotechnology companies of concern, and requires the Director of the Office of Management and Budget to publish a list of such entities within 365 days after enactment.","cite":{"label":"Sec. 2","href":"https://www.congress.gov/bill/118th-congress/house-bill/8333/text/eh#HFB7578370D68498F99182F950F1097B7"}},{"text":"Allows case-by-case waivers with approval of the Director of the Office of Management and Budget, lasting up to 365 days and extendable once for up to 180 days, with notification and justification sent to congressional committees.","cite":{"label":"Sec. 2","href":"https://www.congress.gov/bill/118th-congress/house-bill/8333/text/eh#HFB7578370D68498F99182F950F1097B7"}},{"text":"Exempts intelligence activities, certain overseas health care services for United States employees and their supporting contractors, and lawfully compiled human multiomic data that is commercially or publicly available.","cite":{"label":"Sec. 2","href":"https://www.congress.gov/bill/118th-congress/house-bill/8333/text/eh#HFB7578370D68498F99182F950F1097B7"}},{"text":"Requires the Director of National Intelligence to complete an assessment of national security risks from human multiomic data of United States citizens held by a foreign adversary within 270 days after enactment, and to report it to congressional committees.","cite":{"label":"Sec. 2","href":"https://www.congress.gov/bill/118th-congress/house-bill/8333/text/eh#HFB7578370D68498F99182F950F1097B7"}}],"unexpected":[{"category":"selective_carve_out","items":[{"cite":{"label":"Sec. 2","href":"https://www.congress.gov/bill/118th-congress/house-bill/8333/text/eh#HFB7578370D68498F99182F950F1097B7"},"heading":"Prohibition on contracting with certain biotechnology providers","effect":"Delays the contractor-related prohibitions for contracts or agreements entered into before the effective date. For the companies named in (f)(2)(A) the delay runs until January 1, 2032. For companies designated under (f)(2)(B) it runs five years after the identifying regulation.","amount":null,"quote":"Prior to January 1, 2032, with respect to biotechnology companies of concern covered by subsections (f)(2)(A), subsections (a)(2) and (b)(2) shall not apply to biotechnology equipment or services produced or provided under a contract or agreement"}]}],"version":{"type":"Engrossed in House","date":"2024-09-09","rule":"passed","href":"https://www.congress.gov/bill/118th-congress/house-bill/8333/text/eh"},"current":true,"model":"claude-sonnet-5-5","approved":"2026-09-30","approved_by":"checks"},"sources":{"congress_gov":"https://www.congress.gov/bill/118th-congress/house-bill/8333","text":"https://www.congress.gov/bill/118th-congress/house-bill/8333/text"},"card":{"image":"card/item/118-hr-8333.png","v":"4915efa50eae","alt":"Votes on Record. H.R. 8333, 118th Congress: BIOSECURE Act. House: 306 Yea, 81 Nay. Outcome: Passed House, 9 Sep 2024."}}